TDC
APLS

Thompson Davis & Co’s Apellis Pharmaceuticals APLS Stock Holding History

Thompson Davis & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-125
Closed -$3K – 708
2018
Q2 		$3K Buy
+125
New +$2.87K 0.01% 571

Other funds holding APLS

HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Thompson Davis & Co's APLS Position: Q3 2018 in Review

Thompson Davis & Co sold out of Apellis Pharmaceuticals (APLS) in Q3 2018, closing a stake of 125 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in APLS in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 79 funds tracked by Wall St. Rank hold APLS as of Q3 2018.

  • Thompson Davis & Co reported no remaining Apellis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Apellis Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Thompson Davis & Co first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Apellis Pharmaceuticals position peaked at $3K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.